FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.

被引：0
|
作者：
Li, Qiao
Cheng, Ying
Tong, Zhongsheng
Liu, Yunjiang
Wang, Xian
Yan, Min
Chang, Jianhua
Wang, Shusen
Du, Caiwen
Li, Liang
Wu, Chunjiao
Wang, Mingxia
Wang, Zhuo
Wu, Zhuli
Jin, Yongli
Zhang, Yongjiao
Hui, Ai-Min
Wang, Xingli
Xu, Binghe
机构：
[1] Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China
[2] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Tianjin, Peoples R China
[4] Hebei Med Univ, Dept Breast Ctr, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China
[6] Zhengzhou Univ, Dept Breast Dis, Henan Breast Canc Ctr, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[7] Henan Canc Hosp, Zhengzhou, Peoples R China
[8] Chinese Acad Med Sci, Shenzhen Ctr, Dept Med Oncol, Canc Hosp, Shenzhen, Peoples R China
[9] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[10] Meizhou Peoples Hosp, Dept Med Oncol, Meizhou, Guangdong, Peoples R China
[11] Jilin Canc Hosp, Dept Oncol, Phase ward 1, Changchun, Jilin, Peoples R China
[12] Hebei Med Univ, Dept Phase 1, Clin Trial Unit, Hosp 4, Shijiahuang, Hebei, Peoples R China
[13] Beijing Fosun Pharmaceut Res & Dev Co Ltd, Shanghai, Peoples R China
[14] Fosun Pharma USA Inc, Lexington, MA USA
[15] Shanghai Fosun Pharmaceut Dev Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3044
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS)
    Yamamoto, Yutaka
    Iwata, Hiroji
    Taira, Naruto
    Masuda, Norikazu
    Takahashi, Masato
    Yoshinami, Tetsuhiro
    Ueno, Takayuki
    Toyama, Tatsuya
    Yamanaka, Takashi
    Takano, Toshimi
    Kashiwaba, Masahiro
    Tsugawa, Koichiro
    Hasegawa, Yoshie
    Tamura, Kenji
    Tada, Hiroshi
    Hara, Fumikata
    Fujisawa, Tomomi
    Niikura, Naoki
    Saji, Shigehira
    Morita, Satoshi
    Toi, Masakazu
    Ohno, Shinji
    CANCER SCIENCE, 2022, 113 (09) : 3169 - 3179
  • [2] FS-1502 in patients with HER2 high expression, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: An open-label, multicenter, phase II study
    Pan, Hongming
    Yuan, Xiang-lin
    Zheng, Yu
    Peng, Hui
    Qiu, Hong
    Wang, Jufeng
    Li, Zhiwei
    Gao, Shegan
    Niu, Zuoxing
    Yang, Jianwei
    He, Yifu
    Wu, Guowu
    Yu, Yiyi
    Jieer, Ying
    Wang, Yusheng
    Li, Zhen
    Bai, Jun
    Liu, Huilong
    Wu, Zhuli
    Wang, Xingli
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer
    Pegram, MD
    Pienkowski, T
    Northfelt, DW
    Eiermann, W
    Patel, R
    Fumoleau, P
    Quan, E
    Crown, J
    Toppmeyer, D
    Smylie, M
    Riva, A
    Blitz, S
    Press, MF
    Reese, D
    Lindsay, MA
    Slamon, DJ
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (10): : 759 - 769
  • [4] Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
    Hannelore Denys
    Corina L. Martinez-Mena
    Marc T. Martens
    Randal G. D’Hondt
    Marie-Pascale L. Graas
    Ella Evron
    Georgeta Fried
    Noa E. Ben-Baruch
    Christof Vulsteke
    Mona M. Van Steenberghe
    Breast Cancer Research and Treatment, 2020, 181 : 97 - 105
  • [5] Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
    Denys, Hannelore
    Martinez-Mena, Corina L.
    Martens, Marc T.
    D'Hondt, Randal G.
    Graas, Marie-Pascale L.
    Evron, Ella
    Fried, Georgeta
    Ben-Baruch, Noa E.
    Vulsteke, Christof
    Van Steenberghe, Mona M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 97 - 105
  • [6] Neoadjuvant pyrotinib and inetetamab in combination with chemotherapy for locally advanced HER2-positive breast cancer (NeoPICD study): A prospective, multicenter, open-label, single-arm study.
    Xu, Yiying
    Wu, Xue
    Yang, Chenghui
    Xia, Erjie
    Wang, Yinghao
    Dai, Xuanxuan
    Liu, Haiguang
    Chen, Yizuo
    Wang, Wenqian
    Guo, Guilong
    Wu, Weili
    Li, Xiaoyang
    Wang, Ouchen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
    Chang, Dwan-Ying
    Lin, Chia-Chi
    Chen, Tom Wei-Wu
    Lin, Ching-Hung
    Lee, Jih-Hsiang
    Chao, Ta-Chung
    Liu, Chun-Yu
    Achiwa, Issei
    Kamiyama, Emi
    Okuda, Yasuyuki
    Lee, Caleb
    Chao, Yee
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [8] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    Baselga, Jose
    Bradbury, Ian
    Eidtmann, Holger
    Di Cosimo, Serena
    de Azambuja, Evandro
    Aura, Claudia
    Gomez, Henry
    Dinh, Phuong
    Fauria, Karine
    Van Dooren, Veerle
    Aktan, Gursel
    Goldhirsch, Aron
    Chang, Tsai-Wang
    Horvath, Zsolt
    Coccia-Portugal, Maria
    Domont, Julien
    Tseng, Ling-Min
    Kunz, Georg
    Sohn, Joo Hyuk
    Semiglazov, Vladimir
    Lerzo, Guillermo
    Palacova, Marketa
    Probachai, Volodymyr
    Pusztai, Lajos
    Untch, Michael
    Gelber, Richard D.
    Piccart-Gebhart, Martine
    LANCET, 2012, 379 (9816): : 633 - 640
  • [9] Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
    Chan, Arlene
    Shannon, Catherine
    de Boer, Richard
    Baron-Hay, Sally
    Redfern, Andrew
    Bauwens, Astrid
    Craft, Paul
    Webb, Suzanne
    Townsend, Amanda
    Kotasek, Dusan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (04) : 368 - 375
  • [10] Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
    Murthy, Rashmi
    Borges, Virginia F.
    Conlin, Alison
    Chaves, Jorge
    Chamberlain, Marc
    Gray, Todd
    Vo, Alex
    Hamilton, Erika
    LANCET ONCOLOGY, 2018, 19 (07): : 880 - 888
12345